| | Family Health | Pediatrics
Medulloblastoma: Pediatric vs. Adult Incidence and Risk Factors
Medulloblastoma is the most common malignant pediatric brain tumor (~20% of childhood CNS tumors).
- Peak incidence: Ages 5–9 years.
- Sex bias: Male > female (1.5:1).
- Adults: Rare (<1% of adult brain tumors).
Molecular Subgroups (Prognostic & Therapeutic)
- WNT-activated (best prognosis).
- SHH-activated (intermediate; infant vs. adult differ).
- Group 3 (poor prognosis; often metastatic).
- Group 4 (most common; intermediate).
Treatment
Maximal safe resection → risk-adapted craniospinal irradiation + chemotherapy (cisplatin, vincristine, cyclophosphamide). Survival: ~70–80% overall at 5 years (varies by subgroup/age).
Late effects: neurocognitive, endocrine, hearing, second malignancies – long-term follow-up essential.
Pediatrics - Related Articles
- Crohn's Disease Inheritance: Understanding the Risk & Family Impact
- School Vaccination Impact: Measles, Mumps, Polio Risks
- CT Scans During Pregnancy: Safety, Risks, and Considerations
- Vicks Vaporizer Safety: A Comprehensive Guide for Parents
- Who Performs Baby Ultrasounds? Understanding Ultrasound Professionals
- Supporting Children with Tourette Syndrome: 12 Inclusive Practices
- Pediatrician Career Growth, Job Prospects & Salary Outlook
